Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Gautschi

Showing results (11-20 of 102) with videos related to

Pageof 11
Sort By:
Praxis|February 7, 2013
[Emergency scenario: epidural hematoma - evaluation and management]Martin Stienen, Amr Abdulazim, Gerhard Hildebrandt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2020
Challenges in the Diagnosis of NTRK Fusion-Positive CancersOliver Gautschi, Lukas Bubendorf, Serge Leyvraz, et al.
Onkologie|June 19, 2013
Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancerOliver Gautschi, Hubert Schefer, Christian Riklin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2019
Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung AdenocarcinomaOliver Gautschi, Roopika Menon, Miriam Bertrand, et al.
Clinical Lung Cancer|June 11, 2008
Early clinical trial experience with vaccine therapies in non-small-cell lung cancerCheryl Ho, Adrian F Ochsenbein, Oliver Gautschi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2015
Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancerDaniela Weiler, Joachim Diebold, Klaus Strobel, et al.
Lung Cancer (Amsterdam, Netherlands)|October 31, 2006
Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformationOliver Gautschi, Daniel Ratschiller, Mathias Gugger, et al.
Clinical Lung Cancer|July 16, 2010
Src inhibitors in lung cancer: current status and future directionsSacha I Rothschild, Oliver Gautschi, Eric B Haura, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 15, 2011
Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomitingHenning Burmeister, Stefan Aebi, Cristina Studer, et al.
Translational Lung Cancer Research|January 13, 2023
PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case seriesRao Mushtaq, Alexis B Cortot, Oliver Gautschi, et al.
Pageof 11

Showing results (11-20 of 102) with videos related to

Sort By:
Pageof 11
Praxis|February 7, 2013
[Emergency scenario: epidural hematoma - evaluation and management]Martin Stienen, Amr Abdulazim, Gerhard Hildebrandt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 29, 2020
Challenges in the Diagnosis of NTRK Fusion-Positive CancersOliver Gautschi, Lukas Bubendorf, Serge Leyvraz, et al.
Onkologie|June 19, 2013
Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancerOliver Gautschi, Hubert Schefer, Christian Riklin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 23, 2019
Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung AdenocarcinomaOliver Gautschi, Roopika Menon, Miriam Bertrand, et al.
Clinical Lung Cancer|June 11, 2008
Early clinical trial experience with vaccine therapies in non-small-cell lung cancerCheryl Ho, Adrian F Ochsenbein, Oliver Gautschi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 20, 2015
Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancerDaniela Weiler, Joachim Diebold, Klaus Strobel, et al.
Lung Cancer (Amsterdam, Netherlands)|October 31, 2006
Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformationOliver Gautschi, Daniel Ratschiller, Mathias Gugger, et al.
Clinical Lung Cancer|July 16, 2010
Src inhibitors in lung cancer: current status and future directionsSacha I Rothschild, Oliver Gautschi, Eric B Haura, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 15, 2011
Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomitingHenning Burmeister, Stefan Aebi, Cristina Studer, et al.
Translational Lung Cancer Research|January 13, 2023
PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case seriesRao Mushtaq, Alexis B Cortot, Oliver Gautschi, et al.
Pageof 11